Thermo Fisher Scientific (NYSE:TMO) Upgraded at Hsbc Global Res

Hsbc Global Res upgraded shares of Thermo Fisher Scientific (NYSE:TMO) from a hold rating to a strong-buy rating in a report issued on Monday morning,Zacks.com reports.

Several other research firms also recently weighed in on TMO. Argus boosted their price target on shares of Thermo Fisher Scientific from $580.00 to $610.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. JPMorgan Chase & Co. increased their target price on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a report on Thursday, October 9th. William Blair assumed coverage on Thermo Fisher Scientific in a research note on Monday, August 18th. They issued an “outperform” rating on the stock. Wells Fargo & Company increased their price objective on Thermo Fisher Scientific from $565.00 to $635.00 and gave the company an “overweight” rating in a research note on Thursday, October 23rd. Finally, Morgan Stanley lifted their target price on shares of Thermo Fisher Scientific from $560.00 to $656.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 28th. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $602.35.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock opened at $580.61 on Monday. The firm has a market capitalization of $218.14 billion, a PE ratio of 33.54, a price-to-earnings-growth ratio of 4.28 and a beta of 0.90. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. Thermo Fisher Scientific has a 12 month low of $385.46 and a 12 month high of $610.97. The business’s 50-day moving average price is $555.23 and its 200-day moving average price is $483.27.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.50 by $0.29. The business had revenue of $11.12 billion during the quarter, compared to analyst estimates of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.Thermo Fisher Scientific’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Sell-side analysts forecast that Thermo Fisher Scientific will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be issued a $0.43 dividend. The ex-dividend date is Monday, December 15th. This represents a $1.72 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s payout ratio is 9.94%.

Thermo Fisher Scientific declared that its Board of Directors has initiated a share buyback plan on Thursday, November 6th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to purchase up to 2.4% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s management believes its shares are undervalued.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 17,104 shares of the firm’s stock in a transaction dated Friday, October 24th. The shares were sold at an average price of $573.54, for a total value of $9,809,828.16. Following the completion of the sale, the chief executive officer directly owned 113,762 shares in the company, valued at $65,247,057.48. This trade represents a 13.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Michael D. Shafer sold 10,725 shares of the company’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $600.00, for a total value of $6,435,000.00. Following the transaction, the executive vice president owned 18,731 shares in the company, valued at $11,238,600. This trade represents a 36.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 65,625 shares of company stock worth $38,157,158. Company insiders own 0.33% of the company’s stock.

Institutional Investors Weigh In On Thermo Fisher Scientific

Hedge funds have recently made changes to their positions in the company. Financial Management Network Inc. raised its holdings in Thermo Fisher Scientific by 3.7% in the 3rd quarter. Financial Management Network Inc. now owns 511 shares of the medical research company’s stock worth $248,000 after acquiring an additional 18 shares during the last quarter. Bruce G. Allen Investments LLC lifted its holdings in Thermo Fisher Scientific by 8.8% in the third quarter. Bruce G. Allen Investments LLC now owns 236 shares of the medical research company’s stock valued at $114,000 after acquiring an additional 19 shares during the period. White Pine Capital LLC grew its position in Thermo Fisher Scientific by 3.2% during the third quarter. White Pine Capital LLC now owns 611 shares of the medical research company’s stock valued at $296,000 after buying an additional 19 shares during the period. Elevation Wealth Partners LLC raised its holdings in Thermo Fisher Scientific by 35.1% in the 3rd quarter. Elevation Wealth Partners LLC now owns 77 shares of the medical research company’s stock worth $37,000 after purchasing an additional 20 shares during the period. Finally, Hopwood Financial Services Inc. lifted its position in shares of Thermo Fisher Scientific by 9.1% during the 3rd quarter. Hopwood Financial Services Inc. now owns 239 shares of the medical research company’s stock valued at $116,000 after buying an additional 20 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.